Advancements in Multiple Myeloma Treatment: Frontline Approaches and Therapies for Early Relapse : Episode 2
Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials
Panelists discuss how patient-specific factors like age, comorbidities, cytogenetic risk status, and personal preferences guide decisions to deviate from standard protocols, with particular attention to frailty scores and organ function when considering treatment intensity.
Video content above is prompted by the following:
- How do you decide when to deviate from standard treatment protocols based on patient characteristics?
- Clinical Trial Insights: Please provide a brief overview of the following trials in transplant-preferred newly diagnosed multiple myeloma:
- PERSEUS
- IsKia
- CASSIOPEIA
Recent Videos
Related Content
